Chesley Taft & Associates Has Upped Edwards Lifesciences (EW) Position; Price T Rowe Associates Has Cut Diplomat Pharmacy (DPLO) Holding By $17.67 Million

September 30, 2017 - By Marguerite Chambers

Price T Rowe Associates Inc decreased Diplomat Pharmacy Inc (DPLO) stake by 89.51% reported in 2017Q2 SEC filing. Price T Rowe Associates Inc sold 1.26 million shares as Diplomat Pharmacy Inc (DPLO)’s stock rose 20.96%. The Price T Rowe Associates Inc holds 147,938 shares with $2.19M value, down from 1.41 million last quarter. Diplomat Pharmacy Inc now has $1.41 billion valuation. The stock increased 0.98% or $0.2 on September 29, reaching $20.71. About 686,242 shares traded or 22.22% up from the average. Diplomat Pharmacy Inc (NYSE:DPLO) has declined 40.48% since September 30, 2016 and is downtrending. It has underperformed by 57.18% the S&P500.

Chesley Taft & Associates Llc increased Edwards Lifesciences Corp (EW) stake by 25.87% reported in 2017Q2 SEC filing. Chesley Taft & Associates Llc acquired 6,705 shares as Edwards Lifesciences Corp (EW)’s stock rose 25.80%. The Chesley Taft & Associates Llc holds 32,625 shares with $3.86 million value, up from 25,920 last quarter. Edwards Lifesciences Corp now has $23.08 billion valuation. The stock increased 0.40% or $0.44 on September 29, reaching $109.31. About 1.61 million shares traded or 25.78% up from the average. Edwards Lifesciences Corp (NYSE:EW) has risen 15.41% since September 30, 2016 and is uptrending. It has underperformed by 1.29% the S&P500.

Investors sentiment increased to 2.27 in Q2 2017. Its up 1.06, from 1.21 in 2017Q1. It is positive, as 11 investors sold DPLO shares while 33 reduced holdings. 33 funds opened positions while 67 raised stakes. 47.82 million shares or 1.84% less from 48.72 million shares in 2017Q1 were reported. Tci Wealth Advsr holds 0% or 88 shares. Frontier Capital Management Comm Limited Liability has invested 0.61% in Diplomat Pharmacy Inc (NYSE:DPLO). Legal & General Gp Public Limited Liability Company owns 85,471 shares. Benjamin F Edwards Company has invested 0% in Diplomat Pharmacy Inc (NYSE:DPLO). State Of Alaska Department Of Revenue reported 8,623 shares. Hermes Invest Management has invested 0.39% in Diplomat Pharmacy Inc (NYSE:DPLO). 23,061 are owned by Verition Fund Management Limited Liability Company. Endurant Capital Mngmt Ltd Partnership invested 0.15% in Diplomat Pharmacy Inc (NYSE:DPLO). State Street accumulated 1.27 million shares. Ftb Advsr reported 0% stake. Davis Selected Advisers holds 0.11% in Diplomat Pharmacy Inc (NYSE:DPLO) or 1.70M shares. Northern Corporation owns 1.23M shares. Fcg Ltd has invested 0.17% in Diplomat Pharmacy Inc (NYSE:DPLO). California State Teachers Retirement Systems owns 84,690 shares or 0% of their US portfolio. Continental Advsrs Ltd Liability Corporation has invested 0.11% of its portfolio in Diplomat Pharmacy Inc (NYSE:DPLO).

Price T Rowe Associates Inc increased Connecticut Wtr Svc Inc (NASDAQ:CTWS) stake by 7,720 shares to 38,032 valued at $2.11M in 2017Q2. It also upped Meridian Bancorp Inc Md (NASDAQ:EBSB) stake by 65,819 shares and now owns 5.36 million shares. Liberty Broadband Corp was raised too.

Among 12 analysts covering Diplomat Pharmacy (NYSE:DPLO), 4 have Buy rating, 1 Sell and 7 Hold. Therefore 33% are positive. Diplomat Pharmacy had 24 analyst reports since August 4, 2015 according to SRatingsIntel. The firm has “Neutral” rating by Bank of America given on Wednesday, October 14. Cowen & Co maintained it with “Market Perform” rating and $18 target in Thursday, November 3 report. Mizuho maintained the stock with “Neutral” rating in Thursday, November 3 report. The firm earned “Mkt Perform” rating on Thursday, November 3 by Avondale. As per Tuesday, August 8, the company rating was maintained by Robert W. Baird. Bank of America maintained the shares of DPLO in report on Tuesday, June 7 with “Neutral” rating. The firm has “Buy” rating by Needham given on Tuesday, September 12. UBS initiated the shares of DPLO in report on Wednesday, October 21 with “Buy” rating. The rating was downgraded by Raymond James on Thursday, November 3 to “Market Perform”. Morgan Stanley downgraded Diplomat Pharmacy Inc (NYSE:DPLO) rating on Friday, October 2. Morgan Stanley has “Equal-Weight” rating and $31 target.

Analysts await Diplomat Pharmacy Inc (NYSE:DPLO) to report earnings on November, 1. They expect $0.15 EPS, down 28.57% or $0.06 from last year’s $0.21 per share. DPLO’s profit will be $10.21 million for 34.52 P/E if the $0.15 EPS becomes a reality. After $0.25 actual EPS reported by Diplomat Pharmacy Inc for the previous quarter, Wall Street now forecasts -40.00% negative EPS growth.

Among 26 analysts covering Edwards Lifesciences Corp (NYSE:EW), 20 have Buy rating, 1 Sell and 5 Hold. Therefore 77% are positive. Edwards Lifesciences Corp had 76 analyst reports since July 30, 2015 according to SRatingsIntel. The firm has “Priority List” rating given on Monday, October 19 by Wells Fargo. The firm earned “Outperform” rating on Tuesday, November 8 by Northland Capital. The rating was maintained by Barclays Capital on Wednesday, July 27 with “Equalweight”. As per Tuesday, April 5, the company rating was downgraded by Northland Capital. The rating was maintained by Morgan Stanley with “Overweight” on Wednesday, July 27. The firm earned “Buy” rating on Thursday, July 27 by Northland Capital. On Thursday, July 27 the stock rating was maintained by Canaccord Genuity with “Buy”. Leerink Swann maintained Edwards Lifesciences Corp (NYSE:EW) rating on Monday, April 4. Leerink Swann has “Outperform” rating and $115 target. The firm has “Outperform” rating given on Monday, April 4 by BMO Capital Markets. On Wednesday, July 27 the stock rating was maintained by BTIG Research with “Buy”.